Tuesday, 28.03.2017

Reply (Joseph Knoll)

This is a reply to this comment

I am thankful to Dr. Miklya that instead of going into the details  that selegiline [ (-)-deprenyl] became world-wide known and is still generally viewed and recorded as the first selective inhibitor of B-type monoamine oxidase (MAO), she pointed to the importance of the catecholaminergic activity enhancer (CAE) effect of (-)-deprenyl which determined future research. Her comment brings together how (-)-deprenyl, a b-phenylethylamine (PEA)-derivative, a selective CAE substance allowed to discover that PEA is primarily a natural CAE substance, and how the discovery of enhancer regulation led to the development of R-(-) – 1 – (benzofuran – 2 –yl) – 2 - propylaminopentane [(-)-BPAP], the presently known most potent and selective enhancer of catecholaminergic and serotonergic neurons. Since experimental and clinical studies strongly support the expectation that preventive (-)-deprenyl medication improves the quality and prolongs the duration of life and could prevent or delay the onset of aging-related neurodegenerative diseases, like Parkinson’s and Alzheimer’s, it is unfortunate that the implementation of a proper trial on healthy volunteers to measure the anti-aging effect of Selegiline has still not been undertaken. I am pleased that Dr. Miklya took notice of my statement that to motivate clinicians to think this matter over, inspired my work.

Joseph Knoll
November 7, 20013